Facts and figures

products icon

29.2 million patients use our diabetes products

products icon

Our products are marketed in 170 countries

affiliates icon

We have affiliates in 80 countries

Our products


Main product areas

Diabetes
Obesity
Haemophilia
Growth disorders
Hormone replacement therapy

Our products

 



PERFORMANCE

Annual sale 2018


111,831 million Danish kroner 

Q2 2019


59,372 million Danish kroner

Half-year results for 2019

 

Sales by region
Q2 2019


North America Operations

28,375 million Danish kroner


USA: 26,978 million Danish kroner

Canada: 1,397 million Danish kroner

 

International Operations

30,952 million Danish kroner


Region Europe: 11,367 million Danish kroner

Region AAMEO: 7,285 million Danish kroner

Region China: 6,567 million Danish kroner

Region Japan & Korea: 3,122 million Danish kroner

Region Latin America: 2,611 million Danish kroner

 

Sales by business segment
Q2 2019


Diabetes and obesity care total

50,054 million Danish kroner

 

Biopharmaceuticals total

9,273 million Danish kroner

 


R&D AT A GLANCE
 

research icon

We invest 13.2% of sales in R&D
 

employee icon

19% of our global workforce works within R&D

research icon

We have R&D centres in China, Denmark, India, UK and US


Our research focus



ACCESS TO MEDICINE
 


All people diagnosed with diabetes should receive treatment

Learn more about our access and affordability activities

Graphic: Insulin vials

In 2018, 5 million people with diabetes were treated with our human insulin at a maximum of 4 USD per 10ml vial

Graphic: Children

Our Changing Diabetes in Children® programme has provided treatment to 19,000+ children with type 1 diabetes

Graphic: Donations

In 2018, we donated 85 million Danish kroner to the World Diabetes Foundation
 


OUR PEOPLE
 

Number of employees

More than 41,600 employees (FTEs as of June 2019)


Business area distribution

19% within research and development

33% in production and production administration

38% in international sales and marketing

10% in administration
 

Novo Nordisk employees angaging

Affiliate distribution (FTEs as of July 2019)

Approximately 39% of employees are located in Denmark (16,347 FTEs) and 61% in the rest of the world:

Africa, Asia, Middle East & Oceania: 7,364

China & Taiwan: 4,552

Denmark: 16,347

Europe (excl. HQ): 4,143

Japan (993) & Korea: 1,144

Latin America: 1,982

North America (US 5,766 & Canada 316): 6,082

(includes Novo Nordisk and NNE employees)

 


PRODUCTION AT A GLANCE
 

affiliates icon

We supply nearly half the world's insulin

 

Clean energy icon

By 2020 all our production will run on 100% renewable power

research icon

We have production sites in Brazil, China, Denmark, France and the US


HEADQUARTERS
 

We are located in Denmark

Novo Nordisk A/S
Novo Allé 1
2880 Bagsværd
Denmark
CVR nr. 24 25 67 90

Contact us